| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5886035 | AKORN | Difluoroprostaglandin derivatives and their use |
Dec, 2022
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10864159 | AKORN | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
| US9999593 | AKORN | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
Zioptan is owned by Akorn.
Zioptan contains Tafluprost.
Zioptan has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zioptan are:
- US5886035
Zioptan was authorised for market use on 10 February, 2012.
Zioptan is available in solution/drops;ophthalmic dosage forms.
Zioptan can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The generics of Zioptan are possible to be released after 28 May, 2029.
Drugs and Companies using TAFLUPROST ingredient
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZIOPTAN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic